BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ANCA-Associated Vasculitis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in ANCA-Associated Vascu
 litis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07160608-10336@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:ALXN1820: Phase 2 readout est. (NCT07160608)
DESCRIPTION:ALXN1820\, phase 2\, ANCA-Associated Vasculitis.\nStudy: Safety
  and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil C
 ytoplasmic Antibody (ANCA)-Associated Vasculitis\nEstimated primary comple
 tion: 11 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alxn1820#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07160608
URL:https://assetmemo.bio/drug/alxn1820#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
